First Oncolytic Immunotherapy Improves Durable Response Rate in Melanoma
the Cancer Therapy Advisor take:
Talimogene laherparepvec (T-VEC) is the first oncolytic immunotherapy to demonstrate therapeutic benefit against melanoma in a phase III clinical trial, a new study published online early in the Journal of Clinical Oncology has shown.
For the study, researchers enrolled 436 patients with injectable melanoma that was not surgically resectable and randomly assigned them 2:1 to intralesional T-VEC or subcutaneous granulocyte macrophage colony-stimulating factor (GM-CSF).
Results showed that the durable response rate was 16.3% (95% CI: 12.1-20.5) and 2.1% (95% CI: 0-4.5) in the T-VEC and GM-CSF groups, respectively (OR = 8.9; P < 0.001). In addition, median overall survival was 23.3 months (95% CI: 19.5-29.6) with T-VEC and 18.9 months (95% CI: 16.0-23.7) with GM-CSF (HR = 0.79; 95% CI: 0.62-1.00; P = 0.051).
Researchers found that T-VEC was particularly effective in patients with treatment-naive disease and in patients with stage IIIB, IIIC, or IVM1a melanoma.
In regard to safety, the most common adverse events associated with T-VEC treatment were fatigue, chills, and pyrexia.
T-VEC is a herpes simplex virus type 1-derived oncolytic immunotherapy ultimately designed to enhance systemic antitumor immune response.
Talimogene laherparepvec is the first oncolytic immunotherapy to demonstrate therapeutic benefit against melanoma.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Calcium and Cancer
- Checkpoint Inhibition in Multiple Myeloma After Pembrolizumab-related Clinical Trial Deaths
- NSCLC: Genetic Mutations May Determine Likelihood of Metastasis at Diagnosis
- CAR T Cell Therapy for Acute Lymphoblastic Leukemia: An Evolutionary Perspective
- Atezolizumab Monotherapy Effective in PD-L1 Non-small Cell Lung Cancer
- Platinum Therapy Should Not Be Delayed in Ovarian Cancer Relapse
- Identifying Frail Patients With Multiple Myeloma Improves Treatment Selection
- Outcomes in Pancreatic Cancer Not Improved by Gemcitabine Plus Erlotinib
- Cabozantinib Effective as Salvage Therapy in Thyroid Cancer
- Q&A With Kristian Thidemann Andersen, MD, PhD: Infection in Multiple Myeloma After HDT-ASCT